Aurinia Responds to Now Retracted LinkedIn Post

Audio By Carbonatix

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Sep 29, 2025--

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post referencing voclosporin by an FDA official.

Aurinia stands behind the favorable benefit/risk profile of LUPKYNIS ® (voclosporin). LUPKYNIS received full approval from the FDA in January 2021 based on a large, randomized 52-week clinical study known as AURORA 1. Furthermore, the FDA approved a supplementary new drug application for the long-term use of LUPKYNIS in April 2024 based on the results of AURORA 2, which demonstrated sustained efficacy of LUPKYNIS over a three-year period, with safety comparable to AURORA 1.

Please see Prescribing Information, including Boxed Warning, for LUPKYNIS.

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250929618760/en/

CONTACT: General Inquiries

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CANADA MARYLAND

INDUSTRY KEYWORD: RESEARCH FDA CLINICAL TRIALS OTHER HEALTH BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE OTHER SCIENCE

SOURCE: Aurinia Pharmaceuticals Inc.

Copyright Business Wire 2025.

PUB: 09/29/2025 08:27 PM/DISC: 09/29/2025 08:26 PM

http://www.businesswire.com/news/home/20250929618760/en